Detalhe da pesquisa
1.
First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Clin Transl Sci
; 14(4): 1314-1326, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33503289
2.
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
JAMA Oncol
; 4(11): 1583-1588, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29931076
3.
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
Clin Cancer Res
; 23(10): 2442-2450, 2017 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27810904
4.
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.
Clin Cancer Res
; 23(8): 1955-1966, 2017 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27702821
5.
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).
Clin Cancer Res
; 21(24): 5445-52, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26152744
6.
A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.
Clin Cancer Res
; 20(14): 3683-91, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24807889